Avalon GloboCare Corp.

Listed Company

ALBTCIK 0001630212NasdaqNon-AcceleratedSmaller ReportingServices-Computer Programming ServicesDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-18.26M

Total Assets

$23.40M

Equity

$9.23M

Shares Out

8.02M

Op. Cash Flow

$-4.58M

Business

Avalon GloboCare Corp. is a commercial-stage company developing and delivering precision diagnostic consumer products. It markets the KetoAir breathalyzer device that measures acetone in exhaled breath to indicate ketosis and is paired with an AI Nutritionist app; the company formerly provided laboratory testing services until early 2025. Its business activities include product commercialization, intellectual property development (research presently suspended), and ownership of a commercial real estate subsidiary. Avalon focuses on U.S. commercialization and sells KetoAir via its website and social media, holding exclusive distributorship rights for North America, South America, the EU and the UK.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
INCOME (LOSS) FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO	392,677	−846,588	−9	—	—
Advertising and marketing expenses	843,497	237,671	2	1	328,565
Professional fees	5	2	3	3	5
Compensation and related benefits	1	1	2	2	2
Other general and administrative expenses	784,758	857,869	908,577	886,142	905,800
Total Other Operating Expenses	8	4	7	9	—
LOSS FROM OPERATIONS	−8	−5	−16	−9	−9
Interest expense - amortization of debt discount and debt issuance costs	−1	−1	−544,010	−3	—
Interest expense - other	−320,282	−325,486	−773,780	−185,751	—
Interest expense - related party	—	−42,445	−33,712	—	—
Debt modification charge	—	−838,794	—	—	—
Change in fair value of derivative liability	538,213	374,365	188,374	600,749	—
Loss on extinguishment of debt	−9	—	682,979	—	—
Other income (expense)	67,554	−74,180	−324	223,759	—
Total Other Expense, net	−10	−2	−953,327	−3	—
LOSS BEFORE INCOME TAXES	−18	−7	−17	−12	−9
INCOME TAXES	—	—	—	—	—
NET LOSS FROM CONTINUING OPERATIONS	−18	−7	—	—	—
NET LOSS FROM DISCONTINUED OPERATIONS	−742,103	−863,790	—	—	—
NET LOSS	−18	−8	−17	−12	−9
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST	—	—	—	—	—
NET LOSS AFTER NONCONTROLLING INTEREST	−18	−8	−17	−12	−9
DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS	162,473	—	—	—	—
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS	−18	−8	−17	−12	—
Basic, continuing operations (in Dollars per share)	−5.41	−7.52	—	—	—
Diluted, continuing operations (in Dollars per share)	−5.41	−7.52	—	—	—
Basic, discontinued operations (in Dollars per share)	−0.23	−0.92	—	—	—
Diluted, discontinued operations (in Dollars per share)	−0.23	−0.92	—	—	—
Net Loss Per Common Share Attributable Common Shareholders basic (in Dollars per share)	−5.64	−8.44	−23.8	−1.28	−1.07
Net Loss Per Common Share Attributable Common Shareholders diluted (in Dollars per share)	−5.64	−8.44	−23.8	−1.28	−1.07
Weighted Average Common Shares Outstanding Basic (in Shares)	3	936,614	701,932	9	8
Weighted Average Common Shares Outstanding diluted (in Shares)	3	936,614	701,932	9	8
Unrealized foreign currency translation loss	−9,402	−273	−18,590	−47,871	25,244
COMPREHENSIVE LOSS	−18	−8	−17	−12	−9
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST	—	—	—	—	—
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS	−18	−8	−17	−12	−9

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2022 2022-12-31
Cash	109,091	3	285,400	—	—
Receivable from sale of equity method investment	748,000	—	—	—	—
Prepaid expense and other current assets	282,170	255,084	367,994	—	247,990
Current assets of discontinued operations	356,616	323,232	—	—	—
Total Current Assets	1	3	850,867	—	2
Operating lease right-of-use assets, net	—	4,709	128,250	—	10,885
Property and equipment, net	727	1,298	38,083	—	138,294
Intangible assets, net	2	—	—	—	—
Goodwill	13	—	—	—	—
Equity method investments, net	—	11	12	—	485,008
Non-current assets of discontinued operations	7	7	—	—	—
Total Non-current Assets	22	18	20	—	17
Total Assets	23	21	21	—	20
Accrued professional fees	2	611,462	2	—	2
Accrued research and development fees	153,772	153,772	208,772	—	838,001
Accrued payroll liability and compensation	1	501,258	588,722	—	223,722
Accrued litigation settlement	363,450	373,450	450,000	—	—
Accrued liabilities and other payables	281,063	228,800	272,915	—	283,234
Operating lease obligation	6,000	10,709	129,396	—	11,437
Derivative liability	34,156	127,545	24,796	20,920	—
Stock subscription liability	150,000	—	—	—	—
Bridge loan payable, net	197,341	—	—	—	—
Convertible note payable, net	737,018	2	2	—	—
Current liabilities of discontinued operations	6	6	—	—	—
Total Current Liabilities	14	14	7	—	4
Non-current liabilities of discontinued operations	23,515	—	—	—	—
Total Non-current Liabilities	23,515	—	6	—	5
Total Liabilities	14	14	13	—	9
Commitments and Contingencies (Note 22)	—	—	—	—	—
Preferred stock, Value	—	—	—	—	9
Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,857,476 shares issued and 4,854,009 shares outstanding at December 31, 2025; 1,445,979 shares issued and 1,442,512 shares outstanding at December 31, 2024	486	145	74	—	1,005
Additional paid-in capital	88	72	68	—	66
Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2025 and 2024	−522,500	−522,500	−522,500	—	−522,500
Accumulated deficit	−106	−88	−80	—	−63
Statutory reserve	6,578	6,578	—	—	—
Accumulated other comprehensive loss	−241,402	−232,000	−231,727	—	−213,137
Total Avalon GloboCare Corp. stockholders' equity	9	7	7	—	11
Noncontrolling interest	—	—	—	—	—
Total Equity	9	7	7	—	11
Total Liabilities and Equity	23	21	21	—	20

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization of intangible assets	94,443	611	211,720	330,723	311,761
Amortization of operating lease right-of-use asset	64,388	122,553	118,226	135,557	127,020
Stock-based compensation and service expense	2	521,509	1	1	2
(Income) loss from equity method investment	−392,677	846,588	9	41,863	—
Distribution of earnings from equity method investment	—	611,888	—	—	—
Impairment of laboratory equipment	—	111,033	—	—	—
Debt modification charge	—	688,794	—	—	—
Loss on extinguishment of debt	9	—	—	—	—
Security deposit	17,491	—	396	−416	6,847
Prepaid expense and other assets	−22,299	−106,999	411	−45,996	95,133
Accrued liabilities and other payables	2	−1	−16,601	331,425	1
Accrued liabilities and other payables - related parties	—	−14,051	—	—	—
Operating lease obligation	−64,388	−122,553	−112,915	—	—
NET CASH USED IN OPERATING ACTIVITIES FROM CONTINUING OPERATIONS	−5	−5	—	—	—
Payment for equity interest purchase	—	−100,000	—	−51,999	—
Cash acquired on acquisition	14,026	—	—	—	—
Proceeds from sale of equity method investment	1	—	—	—	—
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES FROM CONTINUING OPERATIONS	1	−100,000	—	—	—
Proceeds from issuance of convertible debt and warrants	—	3	—	—	—
Proceeds from issuance of convertible debt	200,000	—	—	—	—
Payments of convertible debt issuance costs	—	−282,700	−327,200	—	—
Repayments of convertible debt	—	−3	−300,000	—	—
Repayments of loan payable - related party	—	−400,000	—	−410,000	—
Proceeds from stock subscription liability	150,000	—	—	—	—
Advance from pending sale of noncontrolling interest in subsidiary	49,972	2	485,714	—	—
Proceeds from issuance of convertible preferred stock	300,000	4	—	9	—
Payments of convertible preferred stock issuance costs	−10,000	—	—	—	—
Proceeds from issuance of bridge loan	300,000	—	—	—	—
Proceeds from issuance of common stock and warrants	475,500	—	—	—	—
Payments of offering costs	−64,652	—	—	—	—
Proceeds from equity offering	—	3	635,391	—	—
Disbursements for equity offering costs	—	−138,405	−19,132	—	—
NET CASH PROVIDED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS	1	8	5	17	5
Net cash used in operating activities from discontinued operations	−407,434	−289,965	—	—	—
Net cash used in investing activities from discontinued operations	−35,865	—	—	—	—
NET CASH FLOWS USED IN DISCONTINUED OPERATIONS	−443,299	−289,965	—	—	—
EFFECT OF EXCHANGE RATE ON CASH - CONTINUING OPERATIONS	−9,018	1,447	−3,970	10,077	3,443
NET (DECREASE) INCREASE IN CASH	−3	3	−2	1	80,961
Interest	916,643	1	718,753	176,000	—
Common stock issued for future services	8,530	—	—	—	155,700
Common stock issued for accrued liabilities	42,385	60,000	164,871	30,000	276,032
Receivable related to sale of equity method investment	2	—	—	—	—
Related party payable extinguished upon sale of equity method investment	632,916	—	—	—	—
Series B Convertible Preferred Stock extinguished related to sale of equity method investment	11	—	—	—	—
Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock	9	—	—	—	—
Warrants issued as convertible note payable finder's fee	—	40,900	16,977	—	—
Warrants issued with convertible note payable recorded as debt discount	—	438,568	196,193	498,509	—
Common stock issued as convertible note payable commitment fee	26,800	320,546	—	—	—
Equity method investment payable paid by a related party	—	566,667	—	—	—
Reclassification of deferred offering costs	—	175,136	—	—	—
Settlement of derivative liability	176,529	2,354	—	—	—
Issuance of common stock upon cashless exercise of stock warrants	43	4	—	—	—
Initial ROU asset and lease liability	127,486	—	—	—	—
Conversion of convertible note payable and accrued interest into common stock	2	—	236,400	4	—
Deferred financing costs in accrued liabilities	45,000	—	202,892	—	—
Legal fees recorded to receivable from sale of equity method investment	50,000	—	—	—	—
Reclassification of related party loan payable and accrued expenses to advance from related party	—	500,000	—	—	—
Shares issued for adjustments for 1:15 reverse split	—	21	—	—	202,500
Bridge loan issuance costs in accrued liabilities	18,846	—	—	—	—
Common stock issued as convertible note payable commitment fee included in accrued liabilities	138,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro